Therapeutic targeting of transcriptional cyclin-dependent kinases

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Many cancers exhibit transcriptional addiction, driven by dysregulated oncogenic enhancers and transcription factors.
• Transcriptional cyclin-dependent kinases (tCDKs) are increasingly recognized as key regulators in this process.
• Despite initial concerns, targeting tCDKs may offer a therapeutic window for cancer treatment.

Purpose of the Study:

• To review recent advancements in targeting tCDKs for cancer therapy.
• To highlight the development of highly selective tCDK inhibitors.
• To discuss the challenges hindering the clinical application of these inhibitors.

Main Methods:

• Literature review of recent developments in tCDK research.
• Analysis of studies focusing on selective tCDK inhibitors.
• Discussion of challenges and future directions for therapeutic development.

Main Results:

• Dysregulation of tCDKs is a common feature in various cancer types, leading to transcriptional addiction.
• Development of highly selective inhibitors targeting tCDKs has shown promise.
• Evidence suggests a potential therapeutic window for tCDK-targeted therapies.

Conclusions:

• tCDKs represent a viable therapeutic target for cancers exhibiting transcriptional addiction.
• Selective tCDK inhibitors are advancing, but further research is needed.
• Overcoming current challenges is crucial for the successful clinical translation of tCDK-targeted therapies.